oral semaglutide for obesity FDA Approves Semaglutide: First GLP-1 Weight Loss Pill Oral Obesity Drugs Edge Closer

Ozempic (Semaglutide) Injection, For Subcutaneous Use

Keep the bottle tightly closed when not in use and keep out of reach of children

Inform patients about the potential occurrence of GI side effects in the initial weeks of oral semaglutide treatment, particularly during dose escalation periods

This approach was in line with previously published analyses of oral semaglutide, with the exception of the specific HbA1c intensification threshold which was modified to reflect treatment practice in the UK with respect to initiation of injectable diabetes therapies [16, 26, 27]

9 Some of these effects happened even without changes in diet or exercise, though results were stronger when combined with healthy habits

The FDA resolved the semaglutide shortage in late 2024 and the tirzepatide shortage in early 2025, narrowing but not closing the legitimate window